RxDoctor Payments Data

Tessey Jose, MD

Endocrinology, Diabetes & Metabolism · Weston, FLNPI 1285836726

Payments from drug & device makers

$33,040in general payments, 2019–2025

Across 175 payments — averaging $188.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$30K
  • Novo Nordisk$1K
  • Sanofi-aventis U.S. LLC$259
  • Tandem Diabetes Care, Inc.$187
  • Lilly USA, LLC$181
  • Johnson & Johnson$158
  • plus $828 from 13 others

What the payments were for

  • Consulting fees$1,8366%
  • Speaking & faculty fees$24,26673%
  • Travel & lodging$2,1717%
  • Food & beverage$4,73814%
  • Education$290%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,040 in reported general payments places this provider in the 80th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida

Medicare billing

Part B allowed, 2024
$95,032
Medicare patients
316
Services billed
1,314

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide226$325,007
MounjaroTirzepatide82$111,460
TrulicityDulaglutide59$91,817
JardianceEmpagliflozin65$83,205
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/730$52,066
Tresiba Flextouch U-100Insulin Degludec35$22,541
RybelsusSemaglutide11$14,105
Synjardy XrEmpagliflozin/Metformin Hcl15$11,338
NovologInsulin Aspart16$8,808
Insulin Lispro Kwikpen U-100Insulin Lispro17$8,633
SynthroidLevothyroxine Sodium88$8,369
Novolog FlexpenInsulin Aspart31$8,104
Humalog Kwikpen U-100Insulin Lispro24$7,494
Lantus SolostarInsulin Glargine,hum.Rec.Anlog50$6,255
Nano 2nd Gen Pen NeedlePen Needle, Diabetic49$5,666

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$1,277$347,919253 claims
Lilly USA, LLCMounjaro, Trulicity$181$203,277141 claims
Boehringer IngelheimJardiance, Synjardy Xr$94$94,54380 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

Other endocrinology, diabetes & metabolism in Weston

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →